Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9959739 | 1.00 | CA12 (0.52) | CA12CA2KDM4ECA9CA1 | |
| SCHEMBL16935263 | 0.82 | CA12 (0.37) | CA12CA2KDM4ECA9CA1 | |
| SCHEMBL16935266 | 0.82 | CA12 (0.37) | CA12CA2KDM4ECA9CA1 | |
| SCHEMBL16945716 | 0.82 | CA12 (0.37) | CA12CA2KDM4ECA9CA1 | |
| SCHEMBL23229108 | 0.79 | ALOX5 (0.40) | KDM4EBACE1ALOX5ALDH1A1GAA | |
| SCHEMBL5241647 | 0.78 | ALDH1A1 (0.47) | KDM4EBACE1ALOX5ALDH1A1 | |
| SCHEMBL3260265 | 0.78 | ALDH1A1 (0.47) | KDM4EBACE1ALOX5ALDH1A1 | |
| SCHEMBL9754407 | 0.74 | SIRT2 (0.46) | CA12CA2KDM4ECA9CA1 | |
| SCHEMBL14572070 | 0.74 | ABCB1 (0.38) | BACE1ALOX5ALDH1A1GAAPTGES2 | |
| SCHEMBL9754412 | 0.74 | SIRT2 (0.46) | CA12CA2KDM4ECA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655303-B1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH & CIE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20130274487-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084810-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274487-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH TETRADENTATE AMINO/IMINO-THIOETHER BASED RUTHENIUM COMPLEXES | ADH5, ADH1A, ADH1C | CA12 1561/4885CA2 3668/4885KDM4E 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.